gemcitabine, oxaliplatin

Phase 3Small molecule

AstraZeneca

gemcitabine, oxaliplatin is one of 137 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Biliary Tract CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Biliary Tract CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

gemcitabine, oxaliplatin

AstraZeneca

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Tafasitamab

Incyte

Preclinical

7 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Biliary Tract Cancer

NCT05771480

Q4 2026

Phase 3Active, not recruiting

Chemotherapy

NCT03478488

Clinical

Trials by Indication[1]

Locally Advanced1 trial

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT01267344·122 enrolled

Gemcitabine1 trial

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00127595·28 enrolled

Hepatocellular Carcinoma1 trial

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

Completed·YYonsei University·Phase 2·NCT05517239·32 enrolled

Pancreatic Cancer1 trial

A Study of Locally Advanced Pancreatic Cancer

Unknown status·NNational Health Research Institutes, Taiwan·Phase 2·NCT01063192·73 enrolled

Biliary Tract Cancer1 trial

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05771480·142 enrolled

2 more indications

Chemotherapy1 trial

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Active, not recruiting·33D Medicines (Sichuan) Co., Ltd.·Phase 3·NCT03478488·480 enrolled

Lymphoma1 trial

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04948788·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for gemcitabine, oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine, oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine, oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

gemcitabine, oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Locally Advanced1 trial

Gemcitabine1 trial

Hepatocellular Carcinoma1 trial

Pancreatic Cancer1 trial

Biliary Tract Cancer1 trial

Chemotherapy1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News